ATE291899T1 - Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics - Google Patents
Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidicsInfo
- Publication number
- ATE291899T1 ATE291899T1 AT02756105T AT02756105T ATE291899T1 AT E291899 T1 ATE291899 T1 AT E291899T1 AT 02756105 T AT02756105 T AT 02756105T AT 02756105 T AT02756105 T AT 02756105T AT E291899 T1 ATE291899 T1 AT E291899T1
- Authority
- AT
- Austria
- Prior art keywords
- hts
- particle size
- compound
- microfluidics
- high throughput
- Prior art date
Links
- 238000013537 high throughput screening Methods 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000002245 particle Substances 0.000 abstract 2
- 238000010951 particle size reduction Methods 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29973301P | 2001-06-22 | 2001-06-22 | |
| US33009301P | 2001-10-19 | 2001-10-19 | |
| PCT/US2002/016589 WO2003000228A2 (en) | 2001-06-22 | 2002-06-24 | Method for high through put screening using a small scale mill or microfluidics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE291899T1 true ATE291899T1 (de) | 2005-04-15 |
Family
ID=26971379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02756105T ATE291899T1 (de) | 2001-06-22 | 2002-06-24 | Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030087308A1 (de) |
| EP (1) | EP1401401B1 (de) |
| JP (1) | JP2005504266A (de) |
| AT (1) | ATE291899T1 (de) |
| AU (1) | AU2002322019A1 (de) |
| CA (1) | CA2451161A1 (de) |
| DE (1) | DE60203506T2 (de) |
| WO (1) | WO2003000228A2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080102121A1 (en) * | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
| US7758890B2 (en) * | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| WO2003039601A1 (en) * | 2001-11-07 | 2003-05-15 | Imcor Pharmaceutical Company | Methods for vascular imaging using nanoparticulate contrast agents |
| JP4598399B2 (ja) * | 2002-02-04 | 2010-12-15 | エラン ファーマ インターナショナル，リミティド | 表面安定剤としてリゾチームを有するナノ粒子組成物 |
| US20040173696A1 (en) * | 2002-12-17 | 2004-09-09 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
| ES2385332T3 (es) * | 2003-12-05 | 2012-07-23 | Syngenta Participations Ag | Composiciones de mesotriona submicrométricas |
| US20080254114A1 (en) * | 2005-03-03 | 2008-10-16 | Elan Corporation Plc | Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles |
| EP1888037A2 (de) * | 2005-05-10 | 2008-02-20 | Elan Pharma International Limited | Clopidogrel-nanopartikelformulierungen |
| US20110064803A1 (en) * | 2005-05-10 | 2011-03-17 | Elan Pharma International Limited. | Nanoparticulate and controlled release compositions comprising vitamin k2 |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| US20060292214A1 (en) * | 2005-06-03 | 2006-12-28 | Elan Pharma International Limited | Nanoparticulate acetaminophen formulations |
| CN101232870A (zh) * | 2005-06-03 | 2008-07-30 | 伊兰制药国际有限公司 | 纳米微粒甲磺酸伊马替尼制剂 |
| WO2006133045A1 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
| EP1954253A4 (de) | 2005-06-08 | 2011-07-27 | Elan Pharma Int Ltd | Nanoteilchenförmige und kontrolliert freigesetzte zusammensetzungen mit cefditoren |
| EP1898882B1 (de) * | 2005-06-09 | 2009-10-28 | Elan Pharma International Limited | Nanopartikuläre ebastinformulierungen |
| CN101237868A (zh) * | 2005-06-13 | 2008-08-06 | 伊兰制药国际有限公司 | 纳米粒氯吡格雷和阿司匹林组合制剂 |
| CA2614412A1 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International, Limited | Nanoparticulate clarithromycin formulations |
| WO2007033239A2 (en) * | 2005-09-13 | 2007-03-22 | Elan Pharma International, Limited | Nanoparticulate tadalafil formulations |
| EP1933814A2 (de) | 2005-09-15 | 2008-06-25 | Elan Pharma International Limited | Nanoteilchenförmige aripiprazol-formulierungen |
| MX2008015275A (es) * | 2006-05-30 | 2009-02-06 | Elan Pharma Int Ltd | Formulaciones de posaconazol en nanoparticulas. |
| US20080213374A1 (en) * | 2006-07-10 | 2008-09-04 | Elan Pharma International Limited | Nanoparticulate sorafenib formulations |
| MX2009000391A (es) * | 2006-07-12 | 2009-06-30 | Elan Pharma Int Ltd | Formulación de modafinilo en forma de nano-partículas. |
| JP2011520779A (ja) * | 2008-03-21 | 2011-07-21 | エラン・ファルマ・インターナショナル・リミテッド | イマチニブの部位特異的送達のための組成物および使用の方法 |
| WO2010121326A1 (en) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | A novel formulation of naproxen |
| BRPI1014275B8 (pt) | 2009-04-24 | 2021-05-25 | Iceutica Pty Ltd | composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos |
| CA2763456C (en) | 2009-05-27 | 2017-10-24 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
| WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
| US9334200B2 (en) * | 2013-01-28 | 2016-05-10 | Bfp Management, Llc | Fertilizer composition and method for suspending fertilizer in an aqueous solution |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| CN114746083A (zh) | 2019-12-02 | 2022-07-12 | 默克专利股份有限公司 | 活性药物成分的纳米悬浮液在载体上的沉积 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3614980C1 (de) * | 1986-05-02 | 1993-05-27 | Draiswerke Gmbh | Regelungseinrichtung fuer eine Ruehrwerksmuehle |
| US5252459A (en) * | 1988-09-23 | 1993-10-12 | Abbott Laboratories | Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles |
| AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
| US5349957A (en) * | 1992-12-02 | 1994-09-27 | Sterling Winthrop Inc. | Preparation and magnetic properties of very small magnetite-dextran particles |
| US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5401492A (en) * | 1992-12-17 | 1995-03-28 | Sterling Winthrop, Inc. | Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents |
| US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
| US5264610A (en) * | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
| AU679853B2 (en) * | 1994-04-11 | 1997-07-10 | Erich Netzsch Gmbh & Co Holding Kg | Attrition mill |
| US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US5593097A (en) * | 1994-06-10 | 1997-01-14 | Eastman Kodak Company | Micro media mill and method of its use |
| US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
| US5587143A (en) * | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5628981A (en) * | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
| US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5466440A (en) * | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
| US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5593657A (en) * | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
| US5500204A (en) * | 1995-02-10 | 1996-03-19 | Eastman Kodak Company | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging |
| US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
| US5580579A (en) * | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| EP0810853B1 (de) * | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Nanopartikel-dispersionen enthaltende aerosole |
| US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5472683A (en) * | 1995-03-09 | 1995-12-05 | Eastman Kodak Company | Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
| US5573749A (en) * | 1995-03-09 | 1996-11-12 | Nano Systems L.L.C. | Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
| US5643552A (en) * | 1995-03-09 | 1997-07-01 | Nanosystems L.L.C. | Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging |
| US5521218A (en) * | 1995-05-15 | 1996-05-28 | Nanosystems L.L.C. | Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
| US5573750A (en) * | 1995-05-22 | 1996-11-12 | Nanosystems L.L.C. | Diagnostic imaging x-ray contrast agents |
| US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| US5942443A (en) * | 1996-06-28 | 1999-08-24 | Caliper Technologies Corporation | High throughput screening assay systems in microscale fluidic devices |
| WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| US6153225A (en) * | 1998-08-13 | 2000-11-28 | Elan Pharma International Limited | Injectable formulations of nanoparticulate naproxen |
| US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
| US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
| US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| AU5300000A (en) * | 1999-06-01 | 2000-12-18 | Elan Pharma International Limited | Small-scale mill and method thereof |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
-
2002
- 2002-06-24 US US10/177,163 patent/US20030087308A1/en not_active Abandoned
- 2002-06-24 AU AU2002322019A patent/AU2002322019A1/en not_active Abandoned
- 2002-06-24 CA CA002451161A patent/CA2451161A1/en not_active Abandoned
- 2002-06-24 EP EP02756105A patent/EP1401401B1/de not_active Expired - Lifetime
- 2002-06-24 WO PCT/US2002/016589 patent/WO2003000228A2/en not_active Ceased
- 2002-06-24 AT AT02756105T patent/ATE291899T1/de not_active IP Right Cessation
- 2002-06-24 JP JP2003506875A patent/JP2005504266A/ja active Pending
- 2002-06-24 DE DE60203506T patent/DE60203506T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60203506D1 (de) | 2005-05-04 |
| AU2002322019A1 (en) | 2003-01-08 |
| WO2003000228A2 (en) | 2003-01-03 |
| DE60203506T2 (de) | 2006-02-16 |
| EP1401401B1 (de) | 2005-03-30 |
| JP2005504266A (ja) | 2005-02-10 |
| US20030087308A1 (en) | 2003-05-08 |
| WO2003000228A3 (en) | 2003-12-18 |
| CA2451161A1 (en) | 2003-01-03 |
| EP1401401A2 (de) | 2004-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60203506D1 (de) | Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics | |
| Al-Agel et al. | “Turn-off-on” fluorescence probe based functionalized InP quantum wires for detection of cyanide anions | |
| Mark et al. | Bionanofabrication of metallic and semiconductor nanoparticle arrays using S-layer protein lattices with different lateral spacings and geometries | |
| Jaidev et al. | Fungal mediated biosynthesis of silver nanoparticles, characterization and antimicrobial activity | |
| Sun et al. | Synthesis and photoluminescence of ultra-thin ZnO nanowire/nanotube arrays formed by hydrothermal growth | |
| Kathiresan et al. | Studies on silver nanoparticles synthesized by a marine fungus, Penicillium fellutanum isolated from coastal mangrove sediment | |
| Zhang et al. | Comparison of interactions between human serum albumin and silver nanoparticles of different sizes using spectroscopic methods | |
| UA46169C2 (uk) | Спосіб захисту виробів, субстратів та інших цінних паперів від підробки (варіанти), спосіб маркування виробів для способу захисту, композиція покриття, матеріал та частинка для їх здійснення | |
| Kimura et al. | Photoinduced fluorescence enhancement in CdSe/ZnS quantum dot submonolayers sandwiched between insulating layers: influence of dot proximity | |
| Caballero-Díaz et al. | Rapid and simple nanosensor by combination of graphene quantum dots and enzymatic inhibition mechanisms | |
| Plieth et al. | Electrochemical preparation of silver and gold nanoparticles: Characterization by confocal and surface enhanced Raman microscopy | |
| BR0314958A (pt) | Composição reativa de fóton múltiplo, artigo e método para fabricar um compósito orgânico-inorgânico | |
| O’Connor et al. | Commercialization of cellulose nanocrystal (NCC™) production: a business case focusing on the importance of proactive EHS management | |
| Gade et al. | Screening of different species of Phoma for the synthesis of silver nanoparticles | |
| Cárdenas et al. | Synthesis of cadmium sulfide nanoparticles by biomass of Fusarium oxysporum f. sp. lycopersici | |
| Shiratsu et al. | Size dependence of magneto-optical activity in silver nanoparticles with dimensions between 10 and 60 nm studied by MCD spectroscopy | |
| DE602005008556D1 (de) | Wässrige dispersion und ihre verwendung | |
| Almeida et al. | Characterization of silver nanoparticles produced by biosynthesis mediated by Fusarium oxysporum under different processing conditions | |
| Roy et al. | Biosynthesis of silver nanoparticles by Aspergillus foetidus: optimization of physicochemical parameters | |
| WO2004068108A3 (en) | Extracted polarization intensity differential scattering for particle characterization | |
| Gimenez-Ingalaturre et al. | Performance of single-cell ICP-MS for quantitative biodistribution studies of silver interactions with bacteria | |
| Song et al. | Study on AgInZnS-graphene oxide non-toxic quantum dots for biomedical sensing | |
| Liu et al. | Resonance double frequency light scattering of the morin–nucleic acid–cetyltrimethylammonium bromide system and its analytical application | |
| Liu et al. | Synthesis of fluorescent α-chymotrypsin A-functionalized gold nanoclusters and their application to blot-based technology for Hg 2+ detection | |
| Kudrawiec et al. | Influence of non-radiative recombination on photoluminescence decay time in GaInNAs quantum wells with Ga-and In-rich environments of nitrogen atoms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |